

# BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

**Company** 2024/05/09 22:00:00

**Price**  
**222.75**  
USD

**Difference** ▲ 1.38%(3.03)



**Contact Details**

BIOGEN INC. Tel: +1-617-679-2000  
 -- Fax: +  
 225 Binney Street Web: <http://www.biogen.com>  
 02142 Cambridge E-mail: [info@biogen.com](mailto:info@biogen.com)

## Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

## Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
<b>Current assets</b>	6,859,300,000		9,791,200,000		7,856,500,000	
<b>Common stock capital</b>		100,000		100,000		100,000
<b>Fixed assets</b>	19,985,500,000		14,762,900,000		16,020,800,000	
<b>Equity capital of a company</b>		14,799,400,000		13,388,400,000		10,959,700,000
<b>Cash and cash equivalents</b>	1,049,900,000		3,419,300,000		2,261,400,000	
<b>Accrued liabilities</b>		0		0		0
<b>Other assets</b>	-		-		-	
<b>Current liabilities</b>		3,434,300,000		3,272,800,000		4,298,200,000
<b>Prepayments and accrued income</b>	-		-		-	
<b>Non-current liabilities</b>		8,611,100,000		7,892,900,000		8,619,400,000
<b>Different income</b>		-		-		-
<b>Other liabilities</b>		781,100,000		944,200,000		1,320,500,000
<b>Total assets</b>	26,844,800,000	26,844,800,000	24,554,100,000	24,554,100,000	23,877,300,000	23,877,300,000

## Balance notes

	2023	2022	2021
<b>Accounting standard</b>	US-GAAP	US-GAAP	US-GAAP
<b>Employees</b>	7,570	8,725	9,610
<b>Equity ratio</b>	55.13%	54.49%	46.17%
<b>Debt-equity ratio</b>	81.39%	83.53%	116.61%

## Others

	2023	2022	2021
<b>Tax Expense Rate</b>	10.43%	17.62%	3.01%

# BIOGEN IDEC INC.

ISIN: US09062X1037 WKN: 09062X103 Asset Class: **Stock**

## Income statement

	2023	2022	2021
Turnover	9,417,000,000	9,433,400,000	10,402,400,000
Net income	1,161,100,000	3,046,900,000	1,556,100,000
EBIT	1,197,001,430	3,497,669,940	1,879,781,670
Operating income before taxes	1,296,800,000	3,591,800,000	1,745,200,000
Cash Flow	1,547,200,000	1,384,300,000	3,639,900,000
Net interest income	7,900,000	-174,400,000	-278,900,000
Research and development expenses	2,207,800,000	1,958,700,000	2,265,900,000
Income taxes	135,300,000	632,800,000	52,500,000
Result from investments in subsidiaries, associates and other	-	2,600,000	34,900,000
Revenues per employee	1,155,293	1,004,103	1,005,277

## Board of Directors

## Members of Management Board

Caroline Dorsa	Chairman of Board of Directors
Eric Rowinsky	Member of Board of Directors
Maria Freire	Member of Board of Directors
Stephen Sherwin	Member of Board of Directors
Jesus Mantas	Member of Board of Directors
Monish Patolawala	Member of Board of Directors
Susan Langer	Member of Board of Directors
William Hawkins	Member of Board of Directors
Chris Viehbacher	Chairman of Managing Board
Ginger Gregory	Member of Executive Committee
Michael McDonnell	Member of Executive Committee
Nicole Murphy	Member of Executive Committee
Priya Singhal	Member of Executive Committee
Rachid Izzar	Member of Executive Committee
Susan H. Alexander	Member of Executive Committee